Offering Routine and Rapid Point of Care (POC) Syphilis Testing in Pregnant Patients Presenting to the Emergency Department
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Irene Stafford, MD
- Phone Number: (713) 500-6412
- Email: Irene.Stafford@uth.tmc.edu
Study Contact Backup
- Name: Carrie Bakunas, MD
- Phone Number: (713) 500-7878
- Email: Carrie.A.Bakunas@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas Health Science Center at Houston
-
Contact:
- Irene Stafford, MD
- Phone Number: 713-500-6412
- Email: irene.stafford@uth.tmc.edu
-
Contact:
- Carrie Bakunas, MD
- Phone Number: (713) 500-7878
- Email: Carrie.A.Bakunas@uth.tmc.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pregnant individuals that are seeking care at University of Texas, Memorial Herman and Lyndon B Johnson sites ED or obstetrical triage units.
- No Prenatal care during index pregnancy
- No documented syphilis result during the index pregnancy
Exclusion Criteria:
- Pregnant individuals with documented care and syphilis results in the index pregnancy for specific trimester as mandated by Texas law
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Rapid Point of Care (POC) Syphilis testing
|
Participants will undergo the point of care (POC) FDA cleared syphilis health check (SHC) POC test by a research staff using 50 microliters or 1-3 drops of whole blood via finger stick.
The analyzer is handheld, and all testing equipment is temperature stable and does not need refrigeration.
The SHC-Syphilis results will be available within 10 minutes of receipt given the published turnaround time to results of 15 minutes per package insert and will be recorded as a research note in the electronic medical record (EMR) while the provider assigned to the patient and the Houston Health Department will be notified of results and further treatment will be done if results are positive.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of patients without prenatal care during the index pregnancy who received full treatment for all stages of syphilis
Time Frame: within 1 week of presentation until the time of delivery
|
within 1 week of presentation until the time of delivery
|
|
Percentage of patients with no documented syphilis test during the index pregnancy who received full treatment for all stages of syphilis
Time Frame: within 1 week of presentation until the time of delivery
|
within 1 week of presentation until the time of delivery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The percentage of patients who adhere to recommended maternal and newborn longitudinal follow up
Time Frame: within 1 week of presentation until the time of delivery
|
within 1 week of presentation until the time of delivery
|
|
The percentage of patients who adhere to recommended maternal and newborn longitudinal follow up
Time Frame: at time of postpartum (upto 15 months after delivery)
|
at time of postpartum (upto 15 months after delivery)
|
|
Percentage of participants that are married on completion of syphilis treatment
Time Frame: from presentation to delivery
|
from presentation to delivery
|
|
Percentage of participants that have health insurance on completion of syphilis treatment
Time Frame: from presentation to delivery
|
from presentation to delivery
|
|
Percentage of participants that have psychiatric problems on completion of syphilis treatment
Time Frame: from presentation to delivery
|
from presentation to delivery
|
|
Percentage of participants that show substance abuse including alcohol on completion of syphilis treatment
Time Frame: from presentation to delivery
|
from presentation to delivery
|
|
Percentage of participants that have unstable housing on completion of syphilis treatment
Time Frame: from presentation to delivery
|
from presentation to delivery
|
|
Percentage of participants that have transportation on completion of syphilis treatment
Time Frame: from presentation to delivery
|
from presentation to delivery
|
|
Percentage of participants that experience intimate partner violence on completion of syphilis treatment
Time Frame: from presentation to delivery
|
from presentation to delivery
|
|
number of prenatal care visits on completion of syphilis treatment
Time Frame: from presentation to delivery
|
from presentation to delivery
|
|
Percentage of participants that are married on completion of syphilis treatment
Time Frame: at time of postpartum (upto 15 months after delivery)
|
at time of postpartum (upto 15 months after delivery)
|
|
Percentage of participants that have health insurance on completion of syphilis treatment
Time Frame: at time of postpartum (upto 15 months after delivery)
|
at time of postpartum (upto 15 months after delivery)
|
|
Percentage of participants that have psychiatric problems on completion of syphilis treatment
Time Frame: at time of postpartum (upto 15 months after delivery)
|
at time of postpartum (upto 15 months after delivery)
|
|
Percentage of participants that show substance abuse including alcohol on completion of syphilis treatment
Time Frame: at time of postpartum (upto 15 months after delivery)
|
at time of postpartum (upto 15 months after delivery)
|
|
Percentage of participants that have unstable housing on completion of syphilis treatment
Time Frame: at time of postpartum (upto 15 months after delivery)
|
at time of postpartum (upto 15 months after delivery)
|
|
Percentage of participants that have transportation on completion of syphilis treatment
Time Frame: at time of postpartum (upto 15 months after delivery)
|
at time of postpartum (upto 15 months after delivery)
|
|
Percentage of participants that experience intimate partner violence on completion of syphilis treatment
Time Frame: at time of postpartum (upto 15 months after delivery)
|
at time of postpartum (upto 15 months after delivery)
|
|
number of prenatal care visits on completion of syphilis treatment
Time Frame: at time of postpartum (upto 15 months after delivery)
|
at time of postpartum (upto 15 months after delivery)
|
|
Number of birth parents that have reinfection
Time Frame: from presentation to delivery
|
from presentation to delivery
|
|
Number of birth parents that have reinfection
Time Frame: at time of postpartum (upto 15 months after delivery)
|
at time of postpartum (upto 15 months after delivery)
|
|
Number of neonates that have congenital syphilis
Time Frame: from presentation to delivery
|
from presentation to delivery
|
|
Number of neonates that have congenital syphilis
Time Frame: at time of postpartum (upto 15 months after delivery)
|
at time of postpartum (upto 15 months after delivery)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Irene Stafford, MD, The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Infections
- Communicable Diseases
- Sexually Transmitted Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Negative Bacterial Infections
- Spirochaetales Infections
- Sexually Transmitted Diseases, Bacterial
- Treponemal Infections
- Syphilis
- Investigative Techniques
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Surgical Equipment
- Equipment and Supplies
- Immunologic Techniques
- Immunologic Tests
- Serologic Tests
- Surgical Instruments
- Syphilis Serodiagnosis
Other Study ID Numbers
Other Study ID Numbers
- HSC-MS-24-0505
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.